OrthoPediatrics (NASDAQ:KIDS) versus PAVmed (NASDAQ:PAVM) Financial Survey

OrthoPediatrics (NASDAQ:KIDS) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Profitability

This table compares OrthoPediatrics and PAVmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-16.31%	-7.01%	-4.86%
PAVmed	-21,914.12%	-146.19%	-18.39%

Insider and Institutional Ownership

69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 31.8% of OrthoPediatrics shares are owned by insiders. Comparatively, 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for OrthoPediatrics and PAVmed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1	1	9	0	2.73
PAVmed	1	1	1	0	2.00

OrthoPediatrics presently has a consensus target price of $24.44, suggesting a potential upside of 31.92%. PAVmed has a consensus target price of $56.00, suggesting a potential upside of 1,022.24%. Given PAVmed’s higher probable upside, analysts plainly believe PAVmed is more favorable than OrthoPediatrics.

Earnings and Valuation

This table compares OrthoPediatrics and PAVmed”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$236.35 million	2.01	-$39.65 million	($1.68)	-11.03
PAVmed	$70,000.00	71.29	$400,000.00	($37.40)	-0.13

PAVmed has lower revenue, but higher earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

OrthoPediatrics has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Summary

OrthoPediatrics beats PAVmed on 10 of the 14 factors compared between the two stocks.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.